Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis

BACKGROUND: Dovitinib is a receptor tyrosine kinase (RTK) inhibitor targeting vascular endothelial growth factor receptors, fibroblast growth factor receptors and platelet-derived growth factor receptor β. Dovitinib is currently in clinical trials for the treatment of hepatocellular carcinoma (HCC)....

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhi-Yuan, Shi, Ming, Peng, Li-Xia, Wei, Wei, Li, Xin-Jian, Guo, Zhi-Xing, Li, Shu-Hong, Zhong, Chong, Qian, Chao-Nan, Guo, Rong-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552726/
https://www.ncbi.nlm.nih.gov/pubmed/23228017
http://dx.doi.org/10.1186/1479-5876-10-245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552726/
https://www.ncbi.nlm.nih.gov/pubmed/23228017
http://dx.doi.org/10.1186/1479-5876-10-245

Ejemplares similares